

Global Gefitinib Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/G47B2C1901D6EN.html>

Date: December 2024

Pages: 168

Price: US\$ 2,800.00 (Single User License)

ID: G47B2C1901D6EN

Abstracts

Report Overview

Gefitinib is a targeted therapy medication used in the treatment of non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene. It works by inhibiting the tyrosine kinase activity of the EGFR, thereby slowing down or stopping the growth of cancer cells.

As of 2023, the global market size for Gefitinib is estimated at approximately USD 300 million. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.75% from 2024 to 2032.

Several key factors are driving the growth of the Gefitinib market. Firstly, the rising incidence of NSCLC worldwide, particularly in developing countries, is increasing the demand for effective treatment options like Gefitinib. Secondly, advancements in precision medicine and personalized cancer therapy are driving the adoption of targeted therapies like Gefitinib. Additionally, ongoing research and development efforts to expand the indications for Gefitinib are expected to further boost market growth.

One prominent trend in the Gefitinib market is the increasing focus on combination therapies. Healthcare providers are exploring the efficacy of combining Gefitinib with other targeted therapies or immunotherapies to improve treatment outcomes and overcome resistance mechanisms. For example, the combination of Gefitinib with chemotherapy or other EGFR inhibitors has shown promising results in clinical trials.

Another trend shaping the Gefitinib market is the growing emphasis on early diagnosis and treatment. With advancements in diagnostic techniques, more patients are being

diagnosed with EGFR mutations at an early stage, leading to the early initiation of Gefitinib therapy. This trend is expected to drive market growth as early treatment has been associated with better outcomes in NSCLC patients.

Regional distribution of the Gefitinib market shows dominance in regions with high incidences of NSCLC, such as Asia Pacific and North America. Countries like China, Japan, and the United States are leading markets for Gefitinib due to the high prevalence of EGFR mutations in NSCLC patients and the availability of advanced healthcare infrastructure supporting targeted therapy.

Despite the positive market outlook, there are challenges that need to be addressed. One key challenge is the development of resistance to Gefitinib over time, leading to treatment failure in some patients. Research into overcoming resistance mechanisms and developing novel treatment strategies is crucial to address this challenge and improve patient outcomes.

In conclusion, the Gefitinib market is poised for steady growth driven by factors such as the increasing incidence of NSCLC, advancements in precision medicine, and the exploration of combination therapies. Regional dominance in markets with high NSCLC prevalence underscores the importance of targeted therapy in cancer treatment. Addressing challenges related to resistance will be essential in sustaining market growth and improving treatment efficacy for NSCLC patients.

This report provides a deep insight into the global Gefitinib market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Gefitinib Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are

planning to foray into the Gefitinib market in any manner.

Global Gefitinib Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

AstraZeneca

Qilu Pharmaceutical

Natco Pharma

Celon Laboratories

Hetero Drugs

Dr Reddy's Laboratories

Zuventus Healthcare

United Biotech

Panacea Biotec

Cipla

Glenmark Pharmaceuticals

Nobel Ilac Sanayii Ve Ticaret

Accure Labs

Cadila Pharmaceuticals

Ethypharm

Flagship Biotech International

Globela Pharma

Jodas Expoin

Nishchay Pharmaceuticals

Sichuan Xieli Pharmaceutical

Market Segmentation (by Type)

10 Tables/Box

30 Tables/Box

90 Tables/Box

Market Segmentation (by Application)

Hospital

Clinic

Drug Center

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-

Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Gefitinib Market

Overview of the regional outlook of the Gefitinib Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Gefitinib Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Gefitinib

1.2 Key Market Segments

1.2.1 Gefitinib Segment by Type

1.2.2 Gefitinib Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 GEFITINIB MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Gefitinib Market Size (M USD) Estimates and Forecasts (2019-2032)

2.1.2 Global Gefitinib Sales Estimates and Forecasts (2019-2032)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

2.4 Macroeconomic Analysis

3 GEFITINIB MARKET COMPETITIVE LANDSCAPE

3.1 Global Gefitinib Sales by Manufacturers (2019-2024)

3.2 Global Gefitinib Revenue Market Share by Manufacturers (2019-2024)

3.3 Gefitinib Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Gefitinib Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Gefitinib Sales Sites, Area Served, Product Type

3.6 Gefitinib Market Competitive Situation and Trends

3.6.1 Gefitinib Market Concentration Rate

3.6.2 Global 5 and 10 Largest Gefitinib Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 GEFITINIB INDUSTRY CHAIN ANALYSIS

4.1 Gefitinib Industry Chain Analysis

- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF GEFITINIB MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
 - 5.5.1 New Product Developments
 - 5.5.2 Mergers & Acquisitions
 - 5.5.3 Expansions
 - 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies

6 GEFITINIB MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Gefitinib Sales Market Share by Type (2019-2024)
- 6.3 Global Gefitinib Market Size Market Share by Type (2019-2024)
- 6.4 Global Gefitinib Price by Type (2019-2024)

7 GEFITINIB MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Gefitinib Market Sales by Application (2019-2024)
- 7.3 Global Gefitinib Market Size (M USD) by Application (2019-2024)
- 7.4 Global Gefitinib Sales Growth Rate by Application (2019-2024)

8 GEFITINIB MARKET SALES BY REGION

- 8.1 Global Gefitinib Sales by Region
 - 8.1.1 Global Gefitinib Sales by Region
 - 8.1.2 Global Gefitinib Sales Market Share by Region
- 8.2 Global Gefitinib Market Size by Region
 - 8.2.1 Global Gefitinib Market Size by Region
 - 8.2.2 Global Gefitinib Market Size Market Share by Region

8.3 North America

8.3.1 North America Gefitinib Sales by Country

8.3.2 North America Gefitinib Market Size by Country

8.3.3 U.S. Market Overview

8.3.4 Canada Market Overview

8.3.5 Mexico Market Overview

8.4 Europe

8.4.1 Europe Gefitinib Sales by Country

8.4.2 Europe Gefitinib Market Size by Country

8.4.3 Germany Market Overview

8.4.4 France Market Overview

8.4.5 U.K. Market Overview

8.4.6 Italy Market Overview

8.4.7 Russia Market Overview

8.5 Asia Pacific

8.5.1 Asia Pacific Gefitinib Sales by Region

8.5.2 China

8.5.3 Japan

8.5.4 South Korea

8.5.5 India

8.5.6 Southeast Asia

8.6 Asia Pacific

8.6.1 Asia Pacific Gefitinib Market Size by Region

8.6.2 Asia Pacific Gefitinib Market Size by Region

8.6.3 China

8.6.4 Japan

8.6.5 South Korea

8.6.6 India

8.6.7 Southeast Asia

8.7 South America

8.7.1 South America Gefitinib Sales by Country

8.7.2 South America Gefitinib Market Size by Country

8.7.3 Brazil

8.7.4 Argentina

8.7.5 Columbia

8.8 Middle East and Africa

8.8.1 Middle East and Africa Gefitinib Sales by Region

8.8.2 Middle East and Africa Gefitinib Market Size by Region

8.8.3 Saudi Arabia

- 8.8.4 UAE
- 8.8.5 Egypt
- 8.8.6 Nigeria
- 8.8.7 South Africa

9 GEFITINIB MARKET PRODUCTION BY REGION

- 9.1 Global Production of Gefitinib by Region (2019-2024)
- 9.2 Global Gefitinib Revenue Market Share by Region (2019-2024)
- 9.3 Global Gefitinib Production, Revenue, Price and Gross Margin (2019-2024)
- 9.4 North America Gefitinib Production
 - 9.4.1 North America Gefitinib Production Growth Rate (2019-2024)
 - 9.4.2 North America Gefitinib Production, Revenue, Price and Gross Margin (2019-2024)
- 9.5 Europe Gefitinib Production
 - 9.5.1 Europe Gefitinib Production Growth Rate (2019-2024)
 - 9.5.2 Europe Gefitinib Production, Revenue, Price and Gross Margin (2019-2024)
- 9.6 Japan Gefitinib Production (2019-2024)
 - 9.6.1 Japan Gefitinib Production Growth Rate (2019-2024)
 - 9.6.2 Japan Gefitinib Production, Revenue, Price and Gross Margin (2019-2024)
- 9.7 China Gefitinib Production (2019-2024)
 - 9.7.1 China Gefitinib Production Growth Rate (2019-2024)
 - 9.7.2 China Gefitinib Production, Revenue, Price and Gross Margin (2019-2024)

10 KEY COMPANIES PROFILE

- 10.1 AstraZeneca
 - 10.1.1 AstraZeneca Gefitinib Basic Information
 - 10.1.2 AstraZeneca Gefitinib Product Overview
 - 10.1.3 AstraZeneca Gefitinib Product Market Performance
 - 10.1.4 AstraZeneca Business Overview
 - 10.1.5 AstraZeneca Gefitinib SWOT Analysis
 - 10.1.6 AstraZeneca Recent Developments
- 10.2 Qilu Pharmaceutical
 - 10.2.1 Qilu Pharmaceutical Gefitinib Basic Information
 - 10.2.2 Qilu Pharmaceutical Gefitinib Product Overview
 - 10.2.3 Qilu Pharmaceutical Gefitinib Product Market Performance
 - 10.2.4 Qilu Pharmaceutical Business Overview
 - 10.2.5 Qilu Pharmaceutical Gefitinib SWOT Analysis

- 10.2.6 Qilu Pharmaceutical Recent Developments
- 10.3 Natco Pharma
 - 10.3.1 Natco Pharma Gefitinib Basic Information
 - 10.3.2 Natco Pharma Gefitinib Product Overview
 - 10.3.3 Natco Pharma Gefitinib Product Market Performance
 - 10.3.4 Natco Pharma Gefitinib SWOT Analysis
 - 10.3.5 Natco Pharma Business Overview
 - 10.3.6 Natco Pharma Recent Developments
- 10.4 Celon Laboratories
 - 10.4.1 Celon Laboratories Gefitinib Basic Information
 - 10.4.2 Celon Laboratories Gefitinib Product Overview
 - 10.4.3 Celon Laboratories Gefitinib Product Market Performance
 - 10.4.4 Celon Laboratories Business Overview
 - 10.4.5 Celon Laboratories Recent Developments
- 10.5 Hetero Drugs
 - 10.5.1 Hetero Drugs Gefitinib Basic Information
 - 10.5.2 Hetero Drugs Gefitinib Product Overview
 - 10.5.3 Hetero Drugs Gefitinib Product Market Performance
 - 10.5.4 Hetero Drugs Business Overview
 - 10.5.5 Hetero Drugs Recent Developments
- 10.6 Dr Reddy's Laboratories
 - 10.6.1 Dr Reddy's Laboratories Gefitinib Basic Information
 - 10.6.2 Dr Reddy's Laboratories Gefitinib Product Overview
 - 10.6.3 Dr Reddy's Laboratories Gefitinib Product Market Performance
 - 10.6.4 Dr Reddy's Laboratories Business Overview
 - 10.6.5 Dr Reddy's Laboratories Recent Developments
- 10.7 Zuventus Healthcare
 - 10.7.1 Zuventus Healthcare Gefitinib Basic Information
 - 10.7.2 Zuventus Healthcare Gefitinib Product Overview
 - 10.7.3 Zuventus Healthcare Gefitinib Product Market Performance
 - 10.7.4 Zuventus Healthcare Business Overview
 - 10.7.5 Zuventus Healthcare Recent Developments
- 10.8 United Biotech
 - 10.8.1 United Biotech Gefitinib Basic Information
 - 10.8.2 United Biotech Gefitinib Product Overview
 - 10.8.3 United Biotech Gefitinib Product Market Performance
 - 10.8.4 United Biotech Business Overview
 - 10.8.5 United Biotech Recent Developments
- 10.9 Panacea Biotec

- 10.9.1 Panacea Biotec Gefitinib Basic Information
- 10.9.2 Panacea Biotec Gefitinib Product Overview
- 10.9.3 Panacea Biotec Gefitinib Product Market Performance
- 10.9.4 Panacea Biotec Business Overview
- 10.9.5 Panacea Biotec Recent Developments
- 10.10 Cipla
 - 10.10.1 Cipla Gefitinib Basic Information
 - 10.10.2 Cipla Gefitinib Product Overview
 - 10.10.3 Cipla Gefitinib Product Market Performance
 - 10.10.4 Cipla Business Overview
 - 10.10.5 Cipla Recent Developments
- 10.11 Glenmark Pharmaceuticals
 - 10.11.1 Glenmark Pharmaceuticals Gefitinib Basic Information
 - 10.11.2 Glenmark Pharmaceuticals Gefitinib Product Overview
 - 10.11.3 Glenmark Pharmaceuticals Gefitinib Product Market Performance
 - 10.11.4 Glenmark Pharmaceuticals Business Overview
 - 10.11.5 Glenmark Pharmaceuticals Recent Developments
- 10.12 Nobel Ilac Sanayii Ve Ticaret
 - 10.12.1 Nobel Ilac Sanayii Ve Ticaret Gefitinib Basic Information
 - 10.12.2 Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Overview
 - 10.12.3 Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Market Performance
 - 10.12.4 Nobel Ilac Sanayii Ve Ticaret Business Overview
 - 10.12.5 Nobel Ilac Sanayii Ve Ticaret Recent Developments
- 10.13 Accure Labs
 - 10.13.1 Accure Labs Gefitinib Basic Information
 - 10.13.2 Accure Labs Gefitinib Product Overview
 - 10.13.3 Accure Labs Gefitinib Product Market Performance
 - 10.13.4 Accure Labs Business Overview
 - 10.13.5 Accure Labs Recent Developments
- 10.14 Cadila Pharmaceuticals
 - 10.14.1 Cadila Pharmaceuticals Gefitinib Basic Information
 - 10.14.2 Cadila Pharmaceuticals Gefitinib Product Overview
 - 10.14.3 Cadila Pharmaceuticals Gefitinib Product Market Performance
 - 10.14.4 Cadila Pharmaceuticals Business Overview
 - 10.14.5 Cadila Pharmaceuticals Recent Developments
- 10.15 Ethypharm
 - 10.15.1 Ethypharm Gefitinib Basic Information
 - 10.15.2 Ethypharm Gefitinib Product Overview
 - 10.15.3 Ethypharm Gefitinib Product Market Performance

- 10.15.4 Ethypharm Business Overview
- 10.15.5 Ethypharm Recent Developments
- 10.16 Flagship Biotech International
 - 10.16.1 Flagship Biotech International Gefitinib Basic Information
 - 10.16.2 Flagship Biotech International Gefitinib Product Overview
 - 10.16.3 Flagship Biotech International Gefitinib Product Market Performance
 - 10.16.4 Flagship Biotech International Business Overview
 - 10.16.5 Flagship Biotech International Recent Developments
- 10.17 Globela Pharma
 - 10.17.1 Globela Pharma Gefitinib Basic Information
 - 10.17.2 Globela Pharma Gefitinib Product Overview
 - 10.17.3 Globela Pharma Gefitinib Product Market Performance
 - 10.17.4 Globela Pharma Business Overview
 - 10.17.5 Globela Pharma Recent Developments
- 10.18 Jodas Expoin
 - 10.18.1 Jodas Expoin Gefitinib Basic Information
 - 10.18.2 Jodas Expoin Gefitinib Product Overview
 - 10.18.3 Jodas Expoin Gefitinib Product Market Performance
 - 10.18.4 Jodas Expoin Business Overview
 - 10.18.5 Jodas Expoin Recent Developments
- 10.19 Nishchay Pharmaceuticals
 - 10.19.1 Nishchay Pharmaceuticals Gefitinib Basic Information
 - 10.19.2 Nishchay Pharmaceuticals Gefitinib Product Overview
 - 10.19.3 Nishchay Pharmaceuticals Gefitinib Product Market Performance
 - 10.19.4 Nishchay Pharmaceuticals Business Overview
 - 10.19.5 Nishchay Pharmaceuticals Recent Developments
- 10.20 Sichuan Xieli Pharmaceutical
 - 10.20.1 Sichuan Xieli Pharmaceutical Gefitinib Basic Information
 - 10.20.2 Sichuan Xieli Pharmaceutical Gefitinib Product Overview
 - 10.20.3 Sichuan Xieli Pharmaceutical Gefitinib Product Market Performance
 - 10.20.4 Sichuan Xieli Pharmaceutical Business Overview
 - 10.20.5 Sichuan Xieli Pharmaceutical Recent Developments

11 GEFITINIB MARKET FORECAST BY REGION

- 11.1 Global Gefitinib Market Size Forecast
- 11.2 Global Gefitinib Market Forecast by Region
 - 11.2.1 North America Market Size Forecast by Country
 - 11.2.2 Europe Gefitinib Market Size Forecast by Country

11.2.3 Asia Pacific Gefitinib Market Size Forecast by Region

11.2.4 South America Gefitinib Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Sales of Gefitinib by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

12.1 Global Gefitinib Market Forecast by Type (2025-2032)

12.1.1 Global Forecasted Sales of Gefitinib by Type (2025-2032)

12.1.2 Global Gefitinib Market Size Forecast by Type (2025-2032)

12.1.3 Global Forecasted Price of Gefitinib by Type (2025-2032)

12.2 Global Gefitinib Market Forecast by Application (2025-2032)

12.2.1 Global Gefitinib Sales (K MT) Forecast by Application

12.2.2 Global Gefitinib Market Size (M USD) Forecast by Application (2025-2032)

13 CONCLUSION AND KEY FINDINGS

I would like to order

Product name: Global Gefitinib Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/G47B2C1901D6EN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G47B2C1901D6EN.html>